Chemistry:BMB-105

From HandWiki

BMB-105 is a serotonin 5-HT2C receptor agonist which is under development for the treatment of excessive appetite and other symptoms in Prader–Willi syndrome.[1][2][3][4] It is taken orally.[1]

The drug is described as a highly selective biased agonist of the serotonin 5-HT2C receptor, with activation of the Gq signaling pathway but minimal β-arrestin recruitment.[4]

BMB-105 is under development by Bright Minds Biosciences.[1][2][3][4] As of November 2025, it is in phase 1 clinical trials.[1][3] The drug is described as a follow-on drug to Bright Mind Bioscience's more advanced candidate BMB-101 and as a potential "best-in-class" medication.[3][4]

The exact chemical structure of BMB-105 does not yet appear to have been disclosed.[1] However, it is known to be a 2-phenylcyclopropylmethylamine (PCPMA) derivative similarly to BMB-101 and to share structural commonalities with tranylcypromine.[4]

See also

  • Serotonin 5-HT2C receptor agonist
  • Phenylcyclopropylmethylamine
  • BMB-101, BMB-201, and BMB-202

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 "BMB 105". 28 January 2026. https://adisinsight.springer.com/drugs/800085290. 
  2. ↑ 2.0 2.1 "Delving into the Latest Updates on BMB-105 with Synapse". 24 January 2026. https://synapse.patsnap.com/drug/7658e1a9cf884bc19fec8cbda384afd3. 
  3. ↑ 3.0 3.1 3.2 3.3 "Can BMB-105 ease insatiable hunger in PWS? Program to find out.". 13 November 2025. https://praderwillinews.com/news/new-pws-program-testing-bmb-105-treatment-easing-insatiable-hunger/. 
  4. ↑ 4.0 4.1 4.2 4.3 4.4 "Overview of Bright Minds Biosciences: Pioneering Serotonin Pharmacology". 2025 AES Annual Meeting, December 5–9, Atlanta, Georgia. 7 December 2025. https://brightmindsbio.com/wp-content/uploads/2025/12/1.-Overview-of-Bright-Minds-Biosciences.-Pioneering-Serotonin-Pharmacology-_compressed.pdf. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:BMB-105&oldid=4308433"